Paediatric special issue
Introduction to Tripartite Meeting Report (convenors Dr Nigel Baber and Prof. Ros Smyth)
Better medicines for children – where are we now, and where do we want to be?
Tripartite meeting. Paediatric regulatory guidelines
Modelling approaches to dose estimation in children
How children's responses to drugs differ from adults
Formulation of medicines for children
Monitoring adverse drug reactions in children using community pharmacies
Utility of routinely acquired primary care data for paediatric disease epidemiology and pharmacoepidemiology
Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling
Allometric relationships between the pharmacokinetics of propofol in rats, children and adults
Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care
Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital
In vitro fertilization and childhood retinoblastoma
Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old
Effect of the Pediatric Exclusivity Provision on children's access to medicines
Changes in availability of paediatric medicines in Australia between 1998 and 2002
Paediatric homoeopathy in general practice
The potential of UK clinical databases in enhancing paediatric medication research